European Union´s Horizon 2020 – Lipum2020-06-23T06:45:31+02:00


Novel Target for Treatment of Chronic Inflammatory Diseases — Notid

505, 2020

The production development at Abzena proceeds successfully

maj 5th, 2020|

At last our fully humanised antibody and lead candidate SOL-116 will be traveling soon. The production development at Abzena proceeds successfully and according to plan. Downstream processing and quality control have been done and SOL-116 is on its way to Umeå. An enthusiastic team is waiting impatiently to continue with further [...]

503, 2020

Dr Kristian Sandberg new board member of Lipum

mars 5th, 2020|

Dr Kristian Sandberg is an associate professor in immunology and an experienced leader in the pharmaceutical industry’s research and development. Sandberg has over 20 years’ experience from AstraZeneca in various functions within R&D, primarily with project leader responsibilities. He has experiences from the development of both protein and conventional small [...]

2502, 2020

Lipum will attend Bio-Europe Spring 2020

februari 25th, 2020|

In March Lipum will attend Bio-Europe Spring, Europe's largest partnership conference for the biotechnology industry. Meet us there! Visit site:

1702, 2020

Lipum kallar till extra bolagsstämma

februari 17th, 2020|

Aktieägarna i Lipum AB, org. nr. 556813-5999, kallas härmed till extra bolagsstämma tisdagen den 3 mars 2020, kl. 13:00 på Tvistevägen 48C i Umeå. Styrelsen föreslår att Dr Kristian Sandberg väljs som ordinarie styrelseledamot i Lipum AB. Ladda ned kallelse här »

1812, 2019

A milestone has been reached

december 18th, 2019|

After an intensive and targeted work, the cell line development of our lead drug candidate SOL-116 has been finalized. Now the production optimization and scale up has been initiated and that will provide access of non-GMP and GMP material during 2020. That will enable toxicity studies and start of clinical [...]

2911, 2019

Professor Anders Fasth joins the scientific advisory board

november 29th, 2019|

Press release November 29, 2019 Lipum has developed a biological drug candidate for treatment of chronic inflammatory diseases and aim for a better treatment of juvenile idiopathic arthritis (JIA), that affects children. Therefore, the scientific advisory board of the company is now strengthened with Anders Fasth, senior professor of pediatric [...]

European Commission Horizon 2020
SME Instrument phase 1 No 744248
SME Instrument phase 2 No 829741

Project title:
Novel Target for Treatment of Chronic Inflammatory Diseases

Project budget:
3.2 M€

Funding from the EU:
2.2 M€



Till toppen